Quantcast
Last updated on April 25, 2014 at 5:25 EDT

Latest Carboplatin Stories

2014-04-08 08:30:08

CALGARY, April 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers (REO 018). The REO 018 study enrolled a total of 167 patients. Patients on the control arm were treated with carboplatin,...

2014-03-13 08:28:11

CALGARY, March 13, 2014 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the year ended December 31, 2014. "In 2013, we reported data from a number of clinical studies, which included our first data correlating specific biomarkers with survival in NSCLC lung cancer patients and culminated with the reporting of our first randomized data in head and neck cancer," said...

2014-01-16 23:24:20

Researchers recommend that drug choice be guided by aspects of the patient’s condition. Raleigh, NC (PRWEB) January 16, 2014 Surviving Mesothelioma is reporting on newly published research suggesting that certain aspects of a peritoneal mesothelioma patient’s condition may have an impact on the toxicity of chemotherapy. A combination of pemetrexed (Alimta) and a platinum-based drug like cisplatin or carboplatin is the drug treatment of choice for patients with pleural mesothelioma,...

2013-11-21 08:26:35

--Company Intends to Proceed Into Follow-On Registration Study in This Indication-- TORONTO, Nov. 21, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC, NASDAQ:ONCY) today announced positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018). Summary...

2013-10-01 12:31:18

CALGARY, Oct. 1, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that abstracts detailing results from two Phase II studies examining the use of REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) and in patients with squamous cell carcinoma of the lung (REO 021), are now available on the International Association for the Study...

2013-08-13 08:29:38

Study found improved overall survival in patients with stage IV squamous NSCLC INDIANAPOLIS, Aug. 13, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that SQUIRE, a recently completed Phase III study, met its primary endpoint, finding that patients with stage IV metastatic squamous non-small cell lung cancer (NSCLC) experienced increased overall survival (OS) when administered necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin as a first-line...

2013-06-04 08:30:42

Results Presented at ASCO 2013 Establish the Safety Profile of MM-121 and Show Preliminary Activity of the Combination of MM-121 and Gemcitabine or Carboplatin or Pemetrexed or Cabazitaxel CAMBRIDGE, Mass., June 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be combined with standard doses of certain cytotoxic agents for investigation as treatment...

2013-06-04 04:21:03

LAUSANNE, Switzerland, June 4, 2013 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer (NSCLC), platinum-refractory...

2013-06-03 08:27:58

CHICAGO, June 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced results from its PRONOUNCE trial of ALIMTA® (pemetrexed for injection) for treatment of nonsquamous non-small cell lung cancer (NSCLC) that was presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. The PRONOUNCE trial compared an ALIMTA (pemetrexed), carboplatin doublet regimen to a paclitaxel, carboplatin and bevacizumab triplet regimen. The study did not...

2013-05-23 08:26:41

OGX-427 ORCA(TM) Program Expands to Include Second Phase 2 Trial in Patients with Advanced Lung Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, May 23, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar(TM) clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer. This trial will be the...